These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 10476216

  • 1. Hepatoma-specific antitumor activity of an albumin enhancer/promoter regulated herpes simplex virus in vivo.
    Miyatake SI, Tani S, Feigenbaum F, Sundaresan P, Toda H, Narumi O, Kikuchi H, Hashimoto N, Hangai M, Martuza RL, Rabkin SD.
    Gene Ther; 1999 Apr; 6(4):564-72. PubMed ID: 10476216
    [Abstract] [Full Text] [Related]

  • 2. Oncolytic recombinant herpes simplex virus for treatment of orthotopic liver tumors in nude mice.
    Chung YS, Miyatake S, Miyamoto A, Miyamoto Y, Dohi T, Tanigawa N.
    Int J Oncol; 2006 Apr; 28(4):793-8. PubMed ID: 16525626
    [Abstract] [Full Text] [Related]

  • 3. Gene therapy using tissue-specific replication competent HSV.
    Miyatake S.
    Hum Cell; 2002 Sep; 15(3):130-7. PubMed ID: 12703543
    [Abstract] [Full Text] [Related]

  • 4. Gene therapy targeting for hepatocellular carcinoma: selective and enhanced suicide gene expression regulated by a hypoxia-inducible enhancer linked to a human alpha-fetoprotein promoter.
    Ido A, Uto H, Moriuchi A, Nagata K, Onaga Y, Onaga M, Hori T, Hirono S, Hayashi K, Tamaoki T, Tsubouchi H.
    Cancer Res; 2001 Apr 01; 61(7):3016-21. PubMed ID: 11306481
    [Abstract] [Full Text] [Related]

  • 5. Retrovirus-mediated gene therapy for hepatocellular carcinoma: selective and enhanced suicide gene expression regulated by human alpha-fetoprotein enhancer directly linked to its promoter.
    Mawatari F, Tsuruta S, Ido A, Ueki T, Nakao K, Kato Y, Tamaoki T, Ishii N, Nakata K.
    Cancer Gene Ther; 1998 Apr 01; 5(5):301-6. PubMed ID: 9824049
    [Abstract] [Full Text] [Related]

  • 6. Identification of the transcriptional regulatory sequences of human calponin promoter and their use in targeting a conditionally replicating herpes vector to malignant human soft tissue and bone tumors.
    Yamamura H, Hashio M, Noguchi M, Sugenoya Y, Osakada M, Hirano N, Sasaki Y, Yoden T, Awata N, Araki N, Tatsuta M, Miyatake SI, Takahashi K.
    Cancer Res; 2001 May 15; 61(10):3969-77. PubMed ID: 11358814
    [Abstract] [Full Text] [Related]

  • 7. Retrovirus-mediated gene therapy for hepatocellular carcinoma with reversely oriented therapeutic gene expression regulated by alpha-fetoprotein enhancer/promoter.
    Ishikawa H, Nakata K, Mawatari F, Ueki T, Tsuruta S, Ido A, Nakao K, Kato Y, Ishii N, Eguchi K.
    Biochem Biophys Res Commun; 2001 Oct 05; 287(4):1034-40. PubMed ID: 11573968
    [Abstract] [Full Text] [Related]

  • 8. Immuno-viral therapy of brain tumors by combination of viral therapy with cancer vaccination using a replication-conditional HSV.
    Toda M, Iizuka Y, Kawase T, Uyemura K, Kawakami Y.
    Cancer Gene Ther; 2002 Apr 05; 9(4):356-64. PubMed ID: 11960286
    [Abstract] [Full Text] [Related]

  • 9. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
    Nanda D, Vogels R, Havenga M, Avezaat CJ, Bout A, Smitt PS.
    Cancer Res; 2001 Dec 15; 61(24):8743-50. PubMed ID: 11751394
    [Abstract] [Full Text] [Related]

  • 10. Eradication of hepatocellular carcinoma xenografts by radiolabelled, lipiodol-inducible gene therapy.
    Kawashita Y, Ohtsuru A, Miki F, Kuroda H, Morishita M, Kaneda Y, Hatsushiba K, Kanematsu T, Yamashita S.
    Gene Ther; 2005 Nov 15; 12(22):1633-9. PubMed ID: 16079887
    [Abstract] [Full Text] [Related]

  • 11. A strict-late viral promoter is a strong tumor-specific promoter in the context of an oncolytic herpes simplex virus.
    Fu X, Meng F, Tao L, Jin A, Zhang X.
    Gene Ther; 2003 Aug 15; 10(17):1458-64. PubMed ID: 12900760
    [Abstract] [Full Text] [Related]

  • 12. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
    Li Y, Yu DC, Chen Y, Amin P, Zhang H, Nguyen N, Henderson DR.
    Cancer Res; 2001 Sep 01; 61(17):6428-36. PubMed ID: 11522637
    [Abstract] [Full Text] [Related]

  • 13. [Treatment of hepatocellular carcinoma with a novel gene-viral therapeutic system CNHK300-murine endostatin].
    Li GC, Nie MM, Yang JM, Su CQ, Sun LC, Qian YZ, Sham J, Fang GE, Wu MC, Qian QJ.
    Zhonghua Yi Xue Za Zhi; 2004 Jun 02; 84(11):943-8. PubMed ID: 15329284
    [Abstract] [Full Text] [Related]

  • 14. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon.
    Akbulut H, Zhang L, Tang Y, Deisseroth A.
    Cancer Gene Ther; 2003 May 02; 10(5):388-95. PubMed ID: 12719708
    [Abstract] [Full Text] [Related]

  • 15. Effective treatment of tumors with strong beta-catenin/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vector.
    Kuroda T, Rabkin SD, Martuza RL.
    Cancer Res; 2006 Oct 15; 66(20):10127-35. PubMed ID: 17047077
    [Abstract] [Full Text] [Related]

  • 16. The role of the E1B 55 kDa gene product in oncolytic adenoviral vectors expressing herpes simplex virus-tk: assessment of antitumor efficacy and toxicity.
    Wildner O, Morris JC.
    Cancer Res; 2000 Aug 01; 60(15):4167-74. PubMed ID: 10945625
    [Abstract] [Full Text] [Related]

  • 17. Preclinical and therapeutic utility of HVJ liposomes as a gene transfer vector for hepatocellular carcinoma using herpes simplex virus thymidine kinase.
    Hasegawa H, Shimada M, Yonemitsu Y, Utsunomiya T, Gion T, Kaneda Y, Sugimachi K.
    Cancer Gene Ther; 2001 Apr 01; 8(4):252-8. PubMed ID: 11393277
    [Abstract] [Full Text] [Related]

  • 18. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
    Jacobs A, Tjuvajev JG, Dubrovin M, Akhurst T, Balatoni J, Beattie B, Joshi R, Finn R, Larson SM, Herrlinger U, Pechan PA, Chiocca EA, Breakefield XO, Blasberg RG.
    Cancer Res; 2001 Apr 01; 61(7):2983-95. PubMed ID: 11306477
    [Abstract] [Full Text] [Related]

  • 19. In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity.
    Toda M, Martuza RL, Kojima H, Rabkin SD.
    J Immunol; 1998 May 01; 160(9):4457-64. PubMed ID: 9574551
    [Abstract] [Full Text] [Related]

  • 20. Suicide gene therapy of human hepatoma and its peritonitis carcinomatosis by a vector of replicative-deficient herpes simplex virus.
    Iwai M, Harada Y, Ishii M, Kashima K, Mazda O, Tamura M, Wolfe D, Goin WF, Glorioso JC.
    Biochem Biophys Res Commun; 2002 Mar 08; 291(4):855-60. PubMed ID: 11866443
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.